ANI Pharmaceuticals
ANIP
101 hedge funds and large institutions have $317M invested in ANI Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 30 increasing their positions, 21 reducing their positions, and 12 closing their positions.
469% more call options, than puts
Call options by funds: $672K | Put options by funds: $118K
258% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 12
121% more capital inflows, than outflows
Capital inflows: $129M | Capital outflows: $58.4M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
43% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 21
40% more funds holding
Funds holding: 72 → 101 (+29)
9.52% more ownership
Funds ownership: 39.08% → 48.6% (+9.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
+$23.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$14.9M |
| 3 |
Perceptive Advisors
New York
|
+$13.8M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
+$9.8M |
| 5 |
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$8.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deerfield Management
New York
|
-$17.2M |
| 2 |
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$9.9M |
| 3 |
Driehaus Capital Management
Chicago,
Illinois
|
-$5.35M |
| 4 |
Penn Capital Management
Philadelphia,
Pennsylvania
|
-$4.05M |
| 5 |
Turner Investments
Berwyn,
Pennsylvania
|
-$4.02M |
ANIP Hedge Fund Activity: Q4 2014 in Review
101 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2014, worth a combined $317M — up 147% from $129M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new ANIP positions and 12 closed out — a net gain of 31 holders — while 30 added to existing stakes and 21 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $23.8M. The largest seller was Deerfield Management, exiting entirely with an estimated $17.2M sold.
- 101 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2014, up from 72 in Q3 2014.
- Funds reported $317M of ANI Pharmaceuticals stock for Q4 2014, up 147% quarter-over-quarter.
- 43 funds opened new ANI Pharmaceuticals positions in Q4 2014 and 12 closed out, a net change of +31 holders.
- The largest ANI Pharmaceuticals buyer in Q4 2014 was Consonance Capital Management, an estimated $23.8M added.
- The largest ANI Pharmaceuticals seller in Q4 2014 was Deerfield Management, an estimated $17.2M sold.
Based on aggregated 13F filings for Q4 2014.